UT M.D. Anderson Cancer Center

UT MD 安德森癌症中心

基本信息

批准号：
7663210
负责人：
MICHAEL Jordan FISCH
金额：
$ 209.18万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
1996
资助国家：
美国
起止时间：
1996-09-30 至 2012-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7663210
关键词：
Address Adult Affect Affective Symptoms American Area Arts Back Belief Cancer Center Cancer Control Cancer Control Research Program Cancer Patient Cancer Survivor Caring Cause of Death Cessation of life Clinical Oncology Clinical Research Clinical Trials Commit Communication Communities Community Clinical Oncology Program Complementary and alternative medicine Conduct Clinical Trials Controlled Clinical Trials Development Diagnosis Disease Doctor of Medicine Faculty Family Fatigue Health Impaired cognition Individual Integrative Medicine Intervention Leadership Life Malignant Neoplasms Measurement Medical Medicine Medicine in Art Mission Modeling Neuropathy Oncologist Outcome Measure Pain Palliative Care Patient Care Patient Outcomes Assessments Patients Population Prevention Prevention Research Rehabilitation therapy Research Research Infrastructure Resources Risk Site Sleep disturbances Structure Symptoms Teaching Hospitals Technology Texas Therapeutic Touch sensation United States Universities University of Texas M D Anderson Cancer Center Woman aging population base cancer care cancer prevention cancer therapy control trial design improved innovation interest knowledge base lifetime risk meetings member men novel oncology patient oriented prevent programs psychologic psychosocial response skills symptom management treatment trial

项目摘要

DESCRIPTION (provided by applicant): Approximately 10 million Americans are cancer survivors living in their communities, and 80% of adult cancer care is delivered in the community oncology setting. To implement clinical trials, make progress at an appropriate pace in cancer medicine, and address the vital needs of an aging population, the clinical research infrastructure must extend into the community oncology setting. Our hypothesis is that enriched clinical trials in cancer control care, especially in the areas of symptom prevention, symptom management, integrative medicine, cancer prevention, cancer control, and cancer treatment can be delivered to patients via state-of-the art medicine in their communities through our Research" Base; and subsequently, important cancer care-related information and approaches can be transferred back from the community to M. D. Anderson Cancer Center to enhance our research programs and our understanding of cancer care. Our plan is to complete our existing cancer treatment trials, and to develop no further treatment trials. We will develop an expanded, focused program of cancer control research in response to the current needs of our community oncologists and the field of cancer medicine, the increased number of cancer survivors and the associated challenges in developing research-driven models of care for this population, and the evolving strengths of the M. D. Anderson research faculty. The specific aims of this proposal are: Aim 1.To conduct interventional clinical trials in the realm of cancer control to enhance the health of patients affected by cancer; Sub-aim 1a: To develop and conduct interventional clinical trials in the realm of palliative care and rehabilitation; Sub-aim 1b: To develop and conduct interventional clinical trials in the realm of supportive oncology; Sub-aim 1c: To develop and conduct interventional trials that utilize interventions in the realm of integrative medicine (sometimes called complementary and alternative medicine); Sub-aim 1d: To develop and conduct interventional trials directed at improving the health of cancer survivors; Sub-aim 1e: To draw upon best practices in symptom assessment and measurement, and to expand the knowledge base in these realms through the conduct of interventional clinical trials that include patient-reported outcome measures; Sub-aim 1f: To incorporate novel Bayesian approaches to the design and analysis of clinical trials that include use of patient- reported outcomes. Aim 2. To exchange medical information, scientific technology, and. best practice standards among our academic cancer center faculty and fellows, other academic centers, and community oncology sites through collaborative development of practical, innovative cancer control trials. Our Research Base is committed to directing our research program toward conducting clinical trials to meet our CCOP members' interests, skills, and practice settings while fulfilling the mission of M. D. Anderson and the NCI to eliminate suffering attributable to cancer and its treatments.

描述（由申请人提供）：大约 1000 万美国人是生活在其社区的癌症幸存者，80% 的成人癌症护理是在社区肿瘤学环境中提供的。为了实施临床试验，以适当的速度在癌症医学方面取得进展，并满足人口老龄化的重要需求，临床研究基础设施必须延伸到社区肿瘤学环境。我们的假设是，丰富的癌症控制护理临床试验，特别是在症状预防、症状管理、综合医学、癌症预防、癌症控制和癌症治疗领域，可以通过最先进的医学向患者提供通过我们的研究基地社区；随后，重要的癌症护理相关信息和方法可以从社区传回 MD 安德森癌症中心，以加强我们的研究项目和我们对癌症护理的理解。我们的计划是完成我们现有的癌症治疗治疗试验，并且不再开展进一步的治疗试验。我们将制定一项扩大的、重点突出的癌症控制研究计划，以满足社区肿瘤学家和癌症医学领域的当前需求、癌症幸存者数量的增加以及为该人群开发研究驱动的护理模式所面临的相关挑战，以及MD安德森研究人员不断发展的优势。该提案的具体目标是：目的 1. 在癌症控制领域开展介入性临床试验，以增强癌症患者的健康；分目标 1a：在姑息治疗和康复领域开发和开展介入临床试验；分目标 1b：在支持性肿瘤学领域开发和开展介入临床试验；分目标 1c：开发和开展利用综合医学（有时称为补充和替代医学）领域干预措施的介入试验；分目标 1d：制定和开展旨在改善癌症幸存者健康的干预试验；分目标 1e：借鉴症状评估和测量方面的最佳实践，并通过进行包括患者报告的结果测量在内的介入性临床试验来扩展这些领域的知识库；子目标 1f：将新颖的贝叶斯方法纳入临床试验的设计和分析，包括使用患者报告的结果。目标 2. 交流医学信息、科学技术。通过合作开发实用、创新的癌症控制试验，在我们的学术癌症中心的教职人员和研究员、其他学术中心和社区肿瘤学中心之间建立最佳实践标准。我们的研究基地致力于指导我们的研究计划进行临床试验，以满足 CCOP 成员的兴趣、技能和实践环境，同时履行 MD 安德森和 NCI 的使命，消除癌症及其治疗带来的痛苦。